Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct 15;8(10):e77411.
doi: 10.1371/journal.pone.0077411. eCollection 2013.

Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo

Affiliations

Minnelide: a novel therapeutic that promotes apoptosis in non-small cell lung carcinoma in vivo

Ilona Rousalova et al. PLoS One. .

Abstract

Background: Minnelide, a pro-drug of triptolide, has recently emerged as a potent anticancer agent. The precise mechanisms of its cytotoxic effects remain unclear.

Methods: Cell viability was studied using CCK8 assay. Cell proliferation was measured real-time on cultured cells using Electric Cell Substrate Impedence Sensing (ECIS). Apoptosis was assayed by Caspase activity on cultured lung cancer cells and TUNEL staining on tissue sections. Expression of pro-survival and anti-apoptotic genes (HSP70, BIRC5, BIRC4, BIRC2, UACA, APAF-1) was estimated by qRTPCR. Effect of Minnelide on proliferative cells in the tissue was estimated by Ki-67 staining of animal tissue sections.

Results: In this study, we investigated in vitro and in vivo antitumor effects of triptolide/Minnelide in non-small cell lung carcinoma (NSCLC). Triptolide/Minnelide exhibited anti-proliferative effects and induced apoptosis in NSCLC cell lines and NSCLC mouse models. Triptolide/Minnelide significantly down-regulated the expression of pro-survival and anti-apoptotic genes (HSP70, BIRC5, BIRC4, BIRC2, UACA) and up-regulated pro-apoptotic APAF-1 gene, in part, via attenuating the NF-κB signaling activity.

Conclusion: In conclusion, our results provide supporting mechanistic evidence for Minnelide as a potential in NSCLC.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: I have read the journal's policy and have the following conflicts: The University of Minnesota has filed a patent for Minnelide, which has been licensed to Minneamrita Therapuetics, LLC. A.K.S. and S.V. have financial interests in this company. A.K.S. and S.V. are also on the inventors on this patent. The other authors declare that they have no competing interests. Minnelide synthesis has been filed under patent WO/2010/129918. This does not alter our adherence to all the PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Triptolide decreases proliferation and viability of NSCLC cells.
A549 cells (right panel) and NCI-H460 cells (left panel) were treated with 25-200 nM of triptolide for times indicated. Proliferation (A, E) and viability (B, F), as well as BrdU incorporation (C, G) were significantly reduced of both cell lines were reduced; however, the cytotoxic effect of triptolide was more pronounced in NCI-H460 cells. The indicator of DNA repair, phosphorylated H2AX, was significantly increased in both cell lines with triptolide treatment as shown (D, H). Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005.
Figure 2
Figure 2. Triptolide induces apoptosis in NSCLC cells.
NSCLC cells were exposed to 100 nM and 200 nM of triptolide for 24 and 48 hours and caspase-3/-7 activities (A, C) and PARP cleavage (B, D) were assessed. Following triptolide treatment caspase-3/-7 activity and cleavage of PARP were significantly increased compare to untreated cells demonstrating apoptosis. Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005. Results were expressed after normalizing to cell viability.
Figure 3
Figure 3. Minnelide leads to tumor regression in xenograft mouse models.
In two xenograft mouse models, A549 (right panel) and NCI-H460 (left panel), tumor volumes were compared between minnelide treated (n = 10) and untreated groups (n = 10). Five days after tumor injection, mice began receiving daily intraperitoneal injections of minnelide at 0.42 mg/kg mouse weight. Control animals were injected with equivalent volumes of phosphate-buffered saline. Suppression of tumor growth occurred in the minnelide treated groups in comparison with the control groups in both xenograft models (A, E). Graphs (B and F) showed significantly decreased tumor volume from animals (A and E). Results were normalized to the untreated group for each cell line and expressed as the mean, Columns, bars, SE. Ki-67 protein expression was significantly decreased in the tumor tissue of minnelide treated group in both mouse models compare to saline treated groups (C and G). In concordance with decreased Ki-67 staining, TUNEL staining shown increased number of apoptotic cells in both mouse models (D and H). Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005.
Figure 4
Figure 4. Triptolide inhibits NF-κB signaling pathway and its transcriptional activity of its target genes.
NF-κB activity was assessed using dual-luciferase reporter assay after 24-hour treatment with TNF-α (20 ng/ml) or TNF-α (20 ng/ml) in combination with 100 nM of triptolide. The NF-κB activity was stimulated in the cells treated only with TNF-α, while it was effectively decreased after 100 nM of triptolide in A549 and NCI-H460 cells (A). Levels of HSF-1 and Hsp70 mRNA expressions were significantly down-regulated in A549 (B and C) and NCI-H460 cells (D and E). Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005.
Figure 5
Figure 5. Triptolide down-regulates anti-apoptotic IAP genes in A549 and NCI-H460 cells.
Triptolide significantly reduces the expression of IAP genes, (A and D) survivin, (B and E) XIAP and (C and F) c-IAP1. Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005.
Figure 6
Figure 6. Triptolide promotes pro-apoptotic condition in A549 and NCI-H460 cells.
Triptolide treatment increased Apaf-1 mRNA expression level in both NSCLC cell lines (A and D). In parallel, caspase-9 activity was increased in both NSCLC cell lines (B and E). Level of UACA mRNA expression was decreased after triptolide treatment (C and F). Columns, mean, bars, SE. Statistical significance of results was calculated with the Student`s t test (N=3) *P = 0.05; **P = 0.005.

Similar articles

Cited by

References

    1. American Cancer Society (2013). ancer Facts Figures 2013. Available: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume.... Accessed 13 March, 2013.
    1. Ries L, Eisner M, Kosary C et al. (2013) ancer Statistics Review, 1975-2002, Bethesda Md, NCI, 2005. Available: http://seer.cancer.gov/csr/1975_2007/index.html. Accessed 13 August 2013.
    1. Kupchan SM, Court WA, Dailey RG, Gilmore CJ Jr, Bryan RF (1972) Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 94: 7194-7195. doi:10.1021/ja00775a078. PubMed: 5072337. - DOI - PubMed
    1. Liu Q (2011) Triptolide and its expanding multiple pharmacological functions. Int Immunopharmacol 11: 377-383. doi:10.1016/j.intimp.2011.01.012. PubMed: 21255694. - DOI - PubMed
    1. Borja-Cacho D, Yokoyama Y, Chugh RK, Mujumdar NR, Dudeja V et al. (2010) TRAIL and triptolide: an effective combination that induces apoptosis in pancreatic cancer cells. J Gastrointest Surg 14: 252-260. doi:10.1007/s11605-009-1065-6. PubMed: 20013316. - DOI - PMC - PubMed

Publication types

MeSH terms